Perioperative treatment with nivolumab and relatlimab provided long-term benefits in adults with stage III-IV, resectable melanoma.

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...

"If immunotherapy eliminates most of the tumor before surgery, then we have sufficiently trained the immune system for an antitumor response, which minimizes the possibility of recurrence," said lead ...

Participants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

For additional historical context, Wu pointed to two recent studies evaluating nivolumab (Opdivo) plus chemotherapy in resectable NSCLC. A neoadjuvant study showed a 24% pCR rate with nivolumab ...

The latest research published in Genes & Diseases unveils groundbreaking insights into the role of the aging process and the associated factor EMP1 in the progression of resectable pancreatic cancer ...

Preoperative chemoradiotherapy for resectable or borderline resectable pancreatic cancer did not show a significant overall survival benefit. Although the outcomes of the secondary end points and ...

NeoADAURA is a randomized global phase III study investigating the efficacy of neoadjuvant osimertinib-containing regimens in patients with resectable EGFR-mutated stage II to IIIB non–small-cell lung ...

Patients with resectable cutaneous squamous-cell carcinoma received cemiplimab, administered at a dose of 350 mg every 3 weeks for up to four doses, before undergoing surgery with curative intent.